Literature DB >> 24392399

Vigabatrin induced Cell loss in the Cerebellar Cortex of Albino Rats.

Deepa Singh1, Sunder Lal Jethani2, Aksh Dubey1.   

Abstract

BACKGROUND: Vigabatrin is used as the drug of choice in resistant epilepsy and infantile spasms. Ataxia, tremors and abnormal gait have been frequently reported following the use of this drug, indicating an involvement of the cerebellum.
OBJECTIVES: The present study was designed to study the histopathological effects of Vigabatrin on the cerebellum of albino rats.
MATERIAL AND METHODS: Albino Rats were divided into an experimental and a control group. Vigabatrin was administered intra-peritoneally to the experimental group in graded doses for a period of 4 weeks. At the end of the treatment period, rats were sacrificed and brains were dissected out. The cerebellum was separated and fixed. Slides were prepared for histological examination.
RESULTS: Decreased cell counts in the cerebellar cortex secondary to toxic injury were found. Severity increased with increasing doses. INTERPRETATION AND
CONCLUSION: Vigabatrin may be neurotoxic and should be used with caution, assessing cerebellar function at regular intervals.

Entities:  

Keywords:  Albino rats; Cell loss; Cerebellum; GABA; Vigabatrin

Year:  2013        PMID: 24392399      PMCID: PMC3879838          DOI: 10.7860/JCDR/2013/6187.3610

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  21 in total

1.  The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial.

Authors:  Andrew L Lux; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Finbar J K O'Callaghan; Christopher M Verity; John P Osborne
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

2.  The management of infantile spasms.

Authors:  Isabelle Desguerre; Rima Nabbout; Olivier Dulac
Journal:  Arch Dis Child       Date:  2008-01-11       Impact factor: 3.791

3.  Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.

Authors:  I Jambaqué; C Chiron; C Dumas; J Mumford; O Dulac
Journal:  Epilepsy Res       Date:  2000-02       Impact factor: 3.045

4.  gamma-Vinyl GABA: effects of chronic administration on the metabolism of GABA and other amino compounds in rat brain.

Authors:  T L Perry; S J Kish; S Hansen
Journal:  J Neurochem       Date:  1979-06       Impact factor: 5.372

5.  Vigabatrin for the treatment of infantile spasms: final report of a randomized trial.

Authors:  Roy D Elterman; W Donald Shields; Richard M Bittman; Sarah A Torri; Stephen M Sagar; Stephen D Collins
Journal:  J Child Neurol       Date:  2010-04-19       Impact factor: 1.987

6.  Randomized trial of vigabatrin in patients with infantile spasms.

Authors:  R D Elterman; W D Shields; K A Mansfield; J Nakagawa
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

7.  A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats.

Authors:  W H Butler; G P Ford; J W Newberne
Journal:  Toxicol Pathol       Date:  1987       Impact factor: 1.902

Review 8.  Treatment of pediatric epilepsy: European expert opinion, 2007.

Authors:  James W Wheless; Dave F Clarke; Alexis Arzimanoglou; Daniel Carpenter
Journal:  Epileptic Disord       Date:  2007-12       Impact factor: 1.819

9.  Vigabatrin and psychosis.

Authors:  J W Sander; Y M Hart; M R Trimble; S D Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

10.  Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.

Authors:  W D Newman; K Tocher; J F Acheson
Journal:  Eye (Lond)       Date:  2002-09       Impact factor: 3.775

View more
  4 in total

1.  Therapeutic effect of the mesenchymal stem cells on vigabatrin-induced retinopathy in adult male albino rat.

Authors:  Ayat Mahmoud Domouky; Walaa M Samy; Walaa A Rashad
Journal:  Anat Cell Biol       Date:  2022-06-30

2.  The Ameliorative Effect of Empagliflozin in Vigabatrin-Induced Cerebellar/Neurobehavioral Deficits: Targeting mTOR/AMPK/SIRT-1 Signaling Pathways.

Authors:  Rabab M Amer; Amira Kamel Eltokhy; Rasha Osama Elesawy; Amany Nagy Barakat; Eman Basha; Omnia Safwat Eldeeb; Alshimaa Aboalsoud; Nancy Mohamed Elgharabawy; Radwa Ismail
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

Review 3.  Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism.

Authors:  P Malaspina; J-B Roullet; P L Pearl; G R Ainslie; K R Vogel; K M Gibson
Journal:  Neurochem Int       Date:  2016-06-14       Impact factor: 3.921

4.  Modulation of vigabatrin induced cerebellar injury: the role of caspase-3 and RIPK1/RIPK3-regulated cell death pathways.

Authors:  Marwa Abd El-Kader; Eman Hamza; Randa El-Gamal; Amira Sobhy Rashed Eladl; Eman Mohamad El Nashar; Mansour A Alghamdi; Omnia S Erfan
Journal:  J Mol Histol       Date:  2021-05-27       Impact factor: 2.611

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.